Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
accrual, admitted, aeruginosain, affinity, Alchemia, alter, amphiphilic, antibody, antigenicity, antimicrobial, architecture, arm, attorney, Authorisation, avoid, banker, Bar, begun, Berkeley, bevacizumab, Bharatt, billion, binding, bioactivity, bioavailability, biodistribution, bonded, bonding, booster, borrowing, breast, broader, bromide, Calpine, carboplatin, cardiovascular, Cardium, certified, certoluzimab, cervical, chance, Chiroscience, Chowrira, CIP, Circuit, cofounder, colon, Colorado, conventional, cool, corroborated, counted, counting, CRL, cure, cured, cycle, cytotoxic, death, debilitating, degradable, Denver, died, diligence, disproportionate, docetaxel, dryer, Duke, easily, Ellence, encompassing, endeavor, energy, epirubicin, ERP, extreme, extremely, Fairleigh, family, Fc, Fellow, fight, filtration, foot, forfeited, fourteen, fragment, Frameworkissued, furniture, gastric, gemcitabine, Gemzar, gene, glomerular, Harmonization, Herceptin, HIV, Hycamtin, immunodeficiency, incorrect, inhibition, inhibitor, InnerCool, insolvency, irrevocable, ischemic, Jillian, labor, linkage, linker, lowest, membrane, men, Merck, methylnaltrexone, microtubular, modulated, modulating, molecular, monotherapy, Moreadith, move, moving, multinational, multitude, mutant, mutation, neck, network, neurological, nonconvertible, nonfinancial, observable, oncolytic, opposed, ORR, ovarian, paclitaxel, Paraplatin, parent, payer, Pearl, pegfilgrastim, peptide, permanent, permanently, PharmaAG, pharmacodynamic, pharmacokinetic, physicochemical, physiological, potency, prostate, protease, Pvt, Randall, rational, RDG, recombinant, rectal, recurring, refusal, regeneration, rejected, relocate, remand, repair, resource, respond, RGD, Ribozyme, ritonavir, scientist, server, slowdown, SmallCap, Society, Southwestern, spite, spread, Stamford, strong, subcutaneously, superseded, tailored, taxane, taxoid, Taxol, territory, Thomsen, tightening, tissue, topoisomerase, topotecan, transport, trastuzumab, uncured, undesignated, Undistributed, unexpectedly, unfettered, unforeseen, unobservable, upgraded, Vancomycin, vascular, Vermont, versatile, warm, water, widespread, women
Removed:
activated, add, adhere, advisory, aeruginosa, Alexza, analogue, API, applied, apprised, Aradigm, assembly, attached, attestation, aura, automated, automatically, bacteria, basal, bear, Biochemistry, Biology, biomedicine, blister, blood, bloodstream, breakthrough, buccal, Byetta, Canada, chamber, cloud, commitment, compensated, conjunction, convenient, coremed, daily, deal, delivering, Diego, differentiate, differentiated, directive, diversified, doctorate, dose, dronabinol, drying, eating, Elam, Emisphere, expiring, explore, fill, filling, formation, formulate, forward, gel, Generex, Georgia, glucose, grow, half, Halozyme, headed, heading, hybrid, impede, incremental, indefinitely, inhaleable, injectable, injection, intention, introduced, Island, loan, lowering, Lund, Mainfield, mannkind, Marine, marinol, mature, medicinal, metered, Microdose, morbidity, mouth, Nevan, noted, Novo, occurrence, onset, ordered, package, parathyroid, particle, patton, payor, Pennsylvania, plant, portability, post, presently, prevailing, principle, processing, project, prolonged, prospective, PTH, pure, qualification, reactive, receiving, remove, reproducible, respiratory, restore, retired, Rhode, routine, SAB, scaled, skyepharma, solubility, sought, spray, sugar, super, supplier, surfactant, Sweden, synthesize, synthetic, tenant, tenure, TOBI, toxicology, tract, Unimed, Vectura, warrant, wholly, wrote, yield, Zoology
Filing tables
Filing exhibits
- 10-K Annual report
- 2.1 Exhibit 2.1
- 10.17 Exhibit 10.17
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.26 Exhibit 10.26
- 10.27 Exhibit 10.27
- 10.28 Exhibit 10.28
- 10.29 Exhibit 10.29
- 10.34 Exhibit 10.34
- 10.35 Exhibit 10.35
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
Related press release
NKTR similar filings
Filing view
External links